The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVAX | -17.63% | -94.27% | -43.55% | -91% |
| S&P | +15.66% | +85.04% | +13.1% | +1,018% |
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
This stock could be a wealth destroyer in the next five years.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $70.45M | -16.6% |
| Gross Profit | $50.65M | 97.1% |
| Gross Margin | 71.90% | 41.5% |
| Market Cap | $1.41B | -30.4% |
| Market Cap / Employee | $1.48M | 0.0% |
| Employees | 952 | -38.3% |
| Net Income | -$202,379.00K | -66.8% |
| EBITDA | -$72,818.00K | 37.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $278.84M | -52.3% |
| Accounts Receivable | $34.17M | -64.0% |
| Inventory | 13.5 | 56.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $246.10M | 10.0% |
| Short Term Debt | $5.04M | -47.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 23.63% | 40.5% |
| Return On Invested Capital | -3140.15% | 28.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $105.79M | 172.4% |
| Operating Free Cash Flow | $107.80M | 174.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 2.42 | 2.79 | 4.90 | - | |
| Price to Book | -2.45 | -1.65 | -13.49 | 37.37 | -1072.51% |
| Price to Sales | 1.89 | 0.91 | 1.03 | 1.32 | -42.10% |
| Price to Tangible Book Value | -1.97 | -1.41 | -5.44 | -18.66 | 502.69% |
| Enterprise Value to EBITDA | -5.47 | 1.19 | 6.38 | -12.15 | 6.61% |
| Total Debt | $263.47M | $228.66M | $228.49M | $251.14M | 7.64% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
